Duloxetine for nerve damage from ADC cancer treatment
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests whether duloxetine, a medicine often used for nerve pain, can help people whose nerves have been damaged by a type of cancer treatment called an antibody-drug conjugate (ADC). If you have had this side effect and it has not gone away, this study may offer a way to manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced cancer (confirmed by biopsy or imaging)
- You have had nerve damage (tingling, numbness, or pain in hands or feet) of at least moderate severity (grade 2 or higher) from an ADC treatment that lasted more than 28 days after stopping the ADC
- Your cancer is stable enough that you can avoid other nerve-damaging drugs (like certain chemotherapies) for 2 months
- Your liver, kidney, and blood counts are adequate (your doctor can check this)
- You are able to follow the study schedule and have a life expectancy of at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether wearing compression stockings can help prevent nerve damage (peripheral neuropathy) caused by a type of chemotherapy called antibody-drug conjugate (ADC) in people with advanced cancers like bladder cancer. If you are starting treatment with an ADC and don't have existing nerve problems, you may be able to join.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This study tests whether wearing special compression and cooling gloves and socks can help prevent nerve damage (numbness and tingling in hands and feet) that sometimes occurs in women receiving a breast cancer medication called UTD1. You would wear these gloves and socks during and after your chemotherapy treatment.
This Phase 2 trial tests duloxetine to see if it safely reduces painful nerve damage caused by chemotherapy (especially taxanes) in people with solid tumors. If you have moderate-to-severe nerve pain and meet lab and heart-safety checks, this study may be an option.
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
This trial is testing the best time to give an antibody-drug conjugate (ADC) to people with advanced breast cancer that is HER2-negative. It aims to find out if giving this treatment after first chemotherapy fails can help slow the cancer's growth.
Hear when a new Solid Tumour trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.